baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

L&S Knock-Out Axsome Therapeutics.../ DE000LX4AAT9 /

11/11/2024 1:38:01 PM	Chg.-0.02	Bid11/11/2024	Ask11/11/2024	Underlying	Strike price	Expiration date	Option type
2.38EUR	-0.83%	2.38 Bid Size: 50,000	2.58 Ask Size: 50,000	-	63.8212 EUR	12/31/2078	Call

GlobeNewswire 8/27 Axsome Therapeutics to Participate in Investor Conferences in September

GlobeNewswire 8/21 Axsome Therapeutics Reaches Agreement to Dismiss Sunosi® (Solriamfetol) Patent Litigation with Sando...

GlobeNewswire 8/5 Axsome Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 7/11 Axsome Therapeutics to Report Second Quarter 2024 Financial Results on August 5

GlobeNewswire 6/5 Axsome Therapeutics Settles Sunosi® (solriamfetol) Patent Litigation with Unichem Laboratories

GlobeNewswire 6/4 Axsome Therapeutics Joins the American Migraine Foundation to Highlight Unmet Treatment Needs During...

GlobeNewswire 6/3 Axsome Therapeutics Supports Alzheimer’s & Brain Awareness Month

GlobeNewswire 5/30 Axsome Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire 5/29 Axsome Therapeutics Highlights Data on Solriamfetol Demonstrating Improvement in Cognitive Function ...

GlobeNewswire 5/28 Axsome Therapeutics Presents Data from Multiple Programs at the 2024 American Society of Clinical Ps...

GlobeNewswire 5/8 Axsome Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire 5/6 Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

GlobeNewswire 5/1 Axsome Therapeutics Recognizes May as Mental Health Awareness Month

GlobeNewswire 4/15 Axsome Therapeutics Highlights Innovative Neuroscience Portfolio at the American Academy of Neurolog...

GlobeNewswire 4/10 Axsome Therapeutics to Report First Quarter 2024 Financial Results on May 6

GlobeNewswire 4/1 Axsome Therapeutics Initiates ENGAGE Phase 3 Trial of Solriamfetol for the Treatment of Binge Eating...

GlobeNewswire 3/25 Axsome Therapeutics Announces Results of CRESCENDO Narcolepsy Patient Survey Demonstrating Unmet Nee...

GlobeNewswire 3/25 Axsome Therapeutics Announces AXS-12 Achieves Primary Endpoint in the SYMPHONY Phase 3 Trial in Narc...

GlobeNewswire 3/19 Axsome Therapeutics Initiates PARADIGM Phase 3 Trial of Solriamfetol for the Treatment of Major Depr...

GlobeNewswire 3/5 Axsome Therapeutics to Present at the Leerink Partners Global Biopharma Conference

GlobeNewswire 2/20 Axsome Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Busines...

GlobeNewswire 1/23 Axsome Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 20

GlobeNewswire 1/4 Axsome Therapeutics Provides Preliminary Fourth Quarter and Full Year 2023 Net Revenue and 2024 Anti...

GlobeNewswire 12/11/2023 Axsome Therapeutics Presents New Data and Post-Hoc Analyses of Auvelity® in Patients with Major Depr...

GlobeNewswire 12/7/2023 Axsome Therapeutics Hosts Solriamfetol Virtual Investor Event with Expert Thought Leaders Today

L&S Knock-Out Axsome Therapeutics.../ DE000LX4AAT9 /

If you wish to receive reply to your feedback, please provide your email address.